MeadowBrook Investment Advisors LLC Has $218,000 Position in Surgery Partners, Inc. (NASDAQ:SGRY)

MeadowBrook Investment Advisors LLC lifted its holdings in shares of Surgery Partners, Inc. (NASDAQ:SGRY) by 16.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,280 shares of the company’s stock after purchasing an additional 1,460 shares during the quarter. MeadowBrook Investment Advisors LLC’s holdings in Surgery Partners were worth $218,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of SGRY. KBC Group NV grew its stake in Surgery Partners by 31.8% in the third quarter. KBC Group NV now owns 2,385 shares of the company’s stock valued at $77,000 after purchasing an additional 576 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in Surgery Partners by 747.6% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,831 shares of the company’s stock valued at $124,000 after purchasing an additional 3,379 shares in the last quarter. Creative Planning bought a new position in Surgery Partners in the third quarter valued at approximately $258,000. Versor Investments LP acquired a new stake in shares of Surgery Partners in the third quarter valued at approximately $271,000. Finally, Empowered Funds LLC acquired a new stake in shares of Surgery Partners in the fourth quarter valued at approximately $245,000.

Insider Buying and Selling at Surgery Partners

In other news, CEO Jason Eric Evans sold 26,520 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $25.65, for a total value of $680,238.00. Following the transaction, the chief executive officer now directly owns 560,698 shares of the company’s stock, valued at $14,381,903.70. The trade was a 4.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO David T. Doherty sold 13,641 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $25.61, for a total value of $349,346.01. Following the transaction, the chief financial officer now directly owns 108,862 shares in the company, valued at approximately $2,787,955.82. This trade represents a 11.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 96,733 shares of company stock worth $2,480,106. Insiders own 2.30% of the company’s stock.

Surgery Partners Stock Performance

Shares of SGRY stock opened at $25.75 on Wednesday. Surgery Partners, Inc. has a twelve month low of $19.50 and a twelve month high of $35.29. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. The stock’s fifty day simple moving average is $21.88 and its 200 day simple moving average is $26.90.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.06). Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The company had revenue of $770.40 million during the quarter, compared to the consensus estimate of $768.99 million. During the same quarter last year, the firm posted $0.15 EPS. The company’s quarterly revenue was up 14.3% on a year-over-year basis. On average, sell-side analysts predict that Surgery Partners, Inc. will post 0.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on SGRY shares. Bank of America started coverage on Surgery Partners in a research report on Monday, December 16th. They issued a “buy” rating and a $30.00 price objective for the company. Royal Bank of Canada cut their price objective on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Macquarie reissued an “outperform” rating and set a $34.00 price target on shares of Surgery Partners in a report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. dropped their price objective on Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $36.56.

Surgery Partners Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.